Kolexia
Sun Xu-Shan Radio-thérapie
Sun Xu-Shan
Radio-thérapie
Le Mittan Annexe Du Hnfc
Montbéliard, France
116 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou Carcinome anaplasique de la thyroïde Tumeurs de la thyroïde Métastase tumorale Métastase lymphatique Tumeurs du poumon

Collaborateurs

Voir plus
Gherga Elisabeta
Gherga Elisabeta
Le Mittan Annexe Du Hnfc, Montbéliard, France
Boulbair Fatiha
Boulbair Fatiha
Le Mittan Annexe Du Hnfc, Montbéliard, France
Thariat Juliette
Thariat Juliette
Centre François-Baclesse, Caen, France
Nguyen-Tan-Hon Thierry
Nguyen-Tan-Hon Thierry
Le Mittan Annexe Du Hnfc, Montbéliard, France

Industries

Voir plus
AstraZeneca
9 collaboration(s)
Dernière en 2023
Amgen
7 collaboration(s)
Dernière en 2023
Bayer
7 collaboration(s)
Dernière en 2023
Vifor
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
853O OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Letter to the Editor: SMAC mimetics inhibit human T cell proliferation and fail to augment type 1 cytokine responses.
Cellular immunology   30 septembre 2023
Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
Future oncology (London, England)   13 juillet 2023
REACH: A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   19 juin 2023
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
European journal of cancer (Oxford, England : 1990)   09 janvier 2023
203P Early remodeling of systemic antitumor T cell immunity in head and neck cancer patients treated by chemoradiation
Abstract Book of the ESMO Immuno-Oncology Congress 2022 7-9 December 2022   01 décembre 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology   28 octobre 2022
LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial: A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Essai Clinique (Debiopharm)   22 juin 2022
Impact of radiotherapy on survival in resected or unresectable anaplastic thyroid carcinomas, a Rare Cancer Network study.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique   14 juin 2022